Roivant Sciences Ltd. - Common Shares (ROIV) closed at $36.62 on November 5, 2026, down 4.2% from the previous close, on volume of 9,180,847 shares (30-day average 6,313,680).
Data as of November 5, 2026.
5-Nov-2026
Leerink Partners Remains a Buy on Roivant Sciences (ROIV)
TipRanks (Mon, 2-Nov 11:43 AM ET)
Globe Newswire (Thu, 29-Oct 9:00 AM ET)
Roivant jumps after Phase 3 NIU data show brepocitinib pushed median time-to-failure past 48 weeks
Market Chameleon (Wed, 21-Oct 6:47 AM ET)
Market Chameleon (Wed, 21-Oct 3:44 AM ET)
Globe Newswire (Wed, 21-Oct 7:00 AM ET)
Globe Newswire (Wed, 21-Oct 7:00 AM ET)
Globe Newswire (Wed, 21-Oct 7:00 AM ET)
Globe Newswire (Wed, 23-Sep 7:00 AM ET)
Globe Newswire (Wed, 23-Sep 7:00 AM ET)
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Roivant Sciences Ltd. - Common Shares trades on the NASDAQ stock market under the symbol ROIV.
As of November 5, 2026, ROIV stock price declined to $36.62 with 9,180,847 million shares trading.
ROIV has a beta of 0.48, meaning it tends to be less sensitive to market movements. ROIV has a correlation of 0.02 to the broad based SPY ETF.
ROIV has a market cap of $26.45 billion. This is considered a Large Cap stock.
Last quarter Roivant Sciences Ltd. - Common Shares reported $1 million in Revenue and -$.34 earnings per share. This fell short of revenue expectation by $-903,840 and exceeded earnings estimates by $.03.
In the last 3 years, ROIV traded as high as $42.50 and as low as $8.47.
The top ETF exchange traded funds that ROIV belongs to (by Net Assets): IJH, VTI, VB, XMMO, VBK.
ROIV has outperformed the market in the last year with a price return of +84.3% while the SPY ETF gained +9.7%. ROIV has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +5.9% and -0.5%, respectively, while the SPY returned -4.7% and -5.2%, respectively.
ROIV support price is $37.24 and resistance is $39.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ROIV shares will trade within this expected range on the day.
